

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	5	Complete if Known
				<i>Application Number</i> 10/560,953
				<i>Filing Date</i> 04/26/07
				<i>First Named Inventor</i> Beverly L. Wolgast
				<i>Art Unit</i> 1624
				<i>Examiner Name</i> Brenda Libby Coleman
				<i>Attorney Docket Number</i> 10426.0064-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A3	US 3795683	03-05-1974	Brossi et al.	
	A6	US 4210729	07-01-1980	Hermans, et al.	
	A7	US 4210749	07-01-1980	Shetty	
	A11	US 4762845	08-09-1988	Chu et al.	
	A15	US 5178786	01-12-1993	Jahnke et al.	
	A16	US 5247080	09-21-1993	Berger et al.	
	A17	US 5275915	01-04-1994	Kojima et al.	
	A18	US 5387685	02-07-1995	Powell et al.	
	A19	US 5412119	05-02-1995	Brussee et al.	
	A20	US 5422355	06-06-1995	White et al.	
	A21	US 5691362	11-25-1997	McCormick et al.	
	A23	US 5856503	01-05-1999	Aebi et al.	
	A25	US 5925651	07-20-1999	Hutchinson	
	A26	US 5939415	08-17-1999	Laufer et al.	
	A27	US 5942535	08-24-1999	Laufer et al.	
	A28	US 5958943	09-28-1999	Laufer et al.	
	A30	US Provisional Appln. No. 60/512,967	N/A	Burbaum et al.	
	A31	US Provisional Appln. No. 60/789,191	N/A	Arena Pharmaceutical	
	A32	US 6087346	07-11-2000	Glennon et al.	
	A33	US 6218385	04-17-2001	Adams et al.	
	A34	US 6900313	05-31-2005	Wasserscheid et al.	
	A36	US 6972295	12-06-2005	Hagmann et al.	
	A37	US 7514422	04-07-2009	Smith et al.	
	A38	US Appln. No. 11/599,050	3/15/2007	Smith et al.	
	A40	US Appln. No. 11/793,473	1/7/2010	Agarwal et al.	
	A41	US Appln. No. 12/225,966	6/4/2009	Weigl et al.	
	A42	US Appln. No. 12/517,625	N/A	Gharbaoui et al.	
	A43	US Provisional Appln. No. 61/268,930	N/A	Arena Pharmaceutical	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

5

Complete if Known

Application Number	10/560,953
Filing Date	04/26/07
First Named Inventor	Beverly L. Wolgast
Art Unit	1624
Examiner Name	Brenda Libby Coleman
Attorney Docket Number	10426.0064-00000

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
	B3	CA 2197789	08-16-1995	Himmelsbach et al.		
	B16	EP 0285287 A3	8/16/1990	Bondinell, et al.		
	B21	EP 987235	12-03-2003	Murphy, et al.		
	B29	JP 06298746	10-25-1994	Kimura et al.		(English abstract)
	B31	JP 08134048	05-28-1996	Ikehira et al.		(English abstract)
	B32	JP 09030960	02-04-1997	Otsuka Pharm Co. Ltd.		
	B34	JP 90987258	03-31-1997	Ikehira		(English abstract)
	B36	WO 02/074746	3/12/2002			
	B40	WO 0248124 A2	06-20-2002	Adam, et al.		
	B41	WO 03000663 A1	01-03-2003	Chiang et al.		
	B43	WO 04037788	5/6/2004	Best et al.		
	B44	WO 2003/027068 A2	04-03-2003	Gailunas et al.		
	B45	WO 2003/062392 A2	07-31-2003	Shankar et al.		
	B46	WO 2005/003096 A1	01-13-2005	Smith et al.		
	B47	WO 2005/019179 A2	03-03-2005	Burbaum et al.		
	B48	WO 2005/042490 A1	5/12/2005	Smith et al.		
	B49	WO 2005/042491 A1	5/12/2005	Smith et al.		
	B50	WO 2006/013209 A2	2/9/2006	Olarte et al.		
	B51	WO 2006/043710	4/27/2006			(English abstract)
	B52	WO 2006/069363 A2	6/29/2006	Agarwai et al.		
	B53	WO 2006/071740 A2	07-06-2006	Behan et al.		
	B54	WO 2007/120517 A3	10/25/2007	Weigl et al.		
	B55	WO 2008/070111 A3	8/7/2008	Gharbaoui, et al.		
	B63	WO 97/24364 A1	07-10-1997	Weiss		
	B66	WO 99/24411 A1	05-20-1999	Louis et al.		
	B67	WO 2007/120517A2	10-25-2007	Weigl et al.		
	B68	WO 2005/019179 A3	03-03-2005	Burbaum et al.		
	B69	WO 2009/111004 A1	09-11-2009	Carlos et al.		
	B70	WO 2008/070111 A2	06-12-2008	Gharbaoui, et al.		

Complete if Known

Sheet

3

of

Application Number 10/560,953

Filing Date 04/26/07

First Named Inventor Beverly L. Wolgast

Art Unit 1624

Examiner Name Brenda Libby Coleman

Attorney Docket Number 10426.0064-00000

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

FOREIGN PATENT DOCUMENTS

B71	WO 2006/069363 A3	05-10-2007	Agarwal et al.		
B72	WO 2003/086306 A3	02-19-2004	Smith et al.		

NONPATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
	C2	Nagase et al., "An anhydrous polymorphic form of trehalose," <i>Carbohydrate Research</i> 337(2), 167-173 (2002)	
	C4	Barnes, "Pharmacological Strategies for Relapse Prevention in Schizophrenia," <i>Psychiatry</i> 3(10): 37-40 (2004)	
	C14	Di Chara G., "Nucleus accumbens shell and core dopamine: differential role in behavior and addiction," <i>Behavioural Brain Research</i> , 137: 75-114 (2002)	
	C15	Di Chiara et al., "Reward System and Addiction: What Dopamine Does and Doesn't Do," <i>Current Opinion in Pharmacology</i> 7:69-76 (2007)	
	C16	Di Matteo et al., "Role of 5-HT _{2C} Receptors in the Control of Central Dopamine Function," <i>Trends in Pharmacological Sciences</i> 22(5):229-232 (2001)	
	C17	Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision, Washington, DC, American Psychiatric Association, 2000*	
	C18	Van Oekelen et al., "5-HT _{2A} and 5-HT _{2C} receptors and their atypical regulation properties," <i>Life Sciences</i> , Vol. 72:pages 2429-2449 (2003)	
	C23	Flannery-Schroeder, "Reducing Anxiety to Prevent Depression," <i>Am. J. Prev. Med.</i> 31 (6S1):S136-S142 (2006)	
	C25	Di Giovanni et al., "Serotonin/dopamine interaction - Focus on 5-HT _{2C} receptor, a new target of psychotropic drugs," <i>Indian Journal of Experimental Biology</i> , Vol. 40:pages 1344-1352 (2002)	
	C26	Gallant et al., "U-22,394A: a controlled evaluation in chronic schizophrenic patients," <i>Current Therapy Research</i> 9(11):579-81(1967)	
	C28	Gerace et al., "Predictors of Weight Increases over 7 Years in Fire Fighters and Paramedics," <i>Preventive Medicine</i> 25:593-600 (1996)	
	C30	Gobert et al., "Serotonin _{2C} Receptors Tonically Suppress the Activity of Mesocortical Dopaminergic and Adrenergic, But Not Serotonergic, Pathways: A Combined Dialysis and Electrophysiological Analysis in the Rat," <i>Synapse</i> 36: 205-221 (2000)	
	C33	Greene et al., <i>Protective Groups in Organic Syntheses</i> , 2nd Ed., Wiley and Sons, NY (1991)*	
	C34	Halford et al., "Serotonergic Drugs: Effects on Appetite Expression and Use for the Treatment of Obesity," <i>Drugs</i> 67(1):27-55 (2007)	
	C39	Helferich et al. "Uber Derivate Einger chinolincarbonsauren," <i>J. Fur Praktische Chemie</i> , Vol 33, 1966, 39-48.	
	C40	Hester et al., "Azepinoindoles. I. Hexahyclroazepino[4,5-b]indoles," <i>J. Med. Chem.</i> 11(1): 101-106 (1968)	
	C42	Higgins et al, "Serotonin and drug reward: focus on 5-HT _{2C} receptors," <i>European</i>	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

5

Complete if Known

Application Number	10/560,953
Filing Date	04/26/07
First Named Inventor	Beverly L. Wolgast
Art Unit	1624
Examiner Name	Brenda Libby Coleman
Attorney Docket Number	10426.0064-00000

NONPATENT LITERATURE DOCUMENTS

	Journal of Pharmacology, 480: 151-162 (2003)	
C43	Hitzig, P., "COMBINED SEROTONIN AND DOPAMINE INDIRECT AGONISTS CORRECT ALCOHOL CRAVING AND ALCOHOL-ASSOCIATED NEUROSES," Journal of Substance Abuse Treatment, 11(5):489-90 (1994)	
C44	Im et al., "Positive Allosteric Modulator of the Human 5-HT _{2C} Receptor," Molecular Pharmacology, 64: 78-84 (2003)	
C50	Jenck et al., "Antiaversive effects of 5HT _{2C} receptor agonists and fluoxetine in a model of panic-like anxiety in rats," European Neuropsychopharmacology 8: 161 (1998)	
C51	Jensen, "Potential Role of New Therapies in Modifying Cardiovascular Risk in Overweight Patients with Metabolic Risk Factors," Obesity 14 (Suppl. 3):143S-149S (2006)	
C54	Karasu et al., (2000) Practice Guideline for the Treatment of Patients with Major Depressive Disorder	
C56	Koplan et al., "Preventing Childhood Obesity: Health in the Balance, Executive summary," (2005)	
C59	Lam RW, Levitt AJ (1999) (eds) Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder, Clinical & Academic Publishing, Vancouver, BC, Canada	
C62	Linda D. Williams, Chemistry Demystified 123 (2003)	
C65	Moline et al., "Postpartum Depression: A Guide for Patients and Families," Expert Consensus Guidelines Series - Treatment of Depression in Woman 2001, March: 112-113 (2001)	
C66	Muller et al., "Intracellular 5-HT _{2C} -receptor dephosphorylation: a new target for treating drug addiction," Trends in Pharmacological Sciences, 27(9):455-58 (2006)	
C69	Woods et al., "Annual Report: Evaluation of New Compounds for Opioid Activity," National Institute on Drug Abuse, Proceedings of the 41st Annual Scientific Meeting (1979) pp. 356-401	
C70	Navarro-Vasquez et al., "A study of aryl radical cyclization in enaminone esters," J. Org. Chem. 67:3213-20 (2002)	
C72	Niendam et al., "Neurocognitive Performance and Functional Disability in the Psychosis Prodrome," Schizophrenia Research 84:100-111 (2006)	
C74	Orioto et al., "Benzolactams-I: Alkylation of 1,2,4,5-tetrahydro-3-methyl-3H-3-benzazepin-2-one with sodium hydride and alkyl halide," Tetrahedron 36:1017-1021 (1980) Pergamon Press Ltd.	
C79	Pawan et al., "Preliminary study on the effects of fenfluramine derivative, 'S992' in man," British Journal of Pharmacology, 41(2): 416P-417P (1971)	
C85	Porras et al., "5-HT _{2A} and 5-HT _{2C/2B} Receptor Subtypes Modulate Dopamine Release Induced in Vivo by Amphetamine and Morphine in Both the Rat Nucleus Accumbens and Striatum," Neuropsychopharmacology 26: 311-324 (2002)	
C86	Prous Science Integrity entry 156186	
C87	Prous Science Integrity entry 354056	
C88	Rothman R.B., "Treatment of Alcohol and Cocaine Addiction by the Combination of Pemoline and Fenfluramine: A Preliminary Case Series," Journal of Substance Abuse Treatment, 12(6):449-53 (1995)	

				Complete if Known	
				<i>Application Number</i>	10/560,953
				<i>Filing Date</i>	04/26/07
				<i>First Named Inventor</i>	Beverly L. Wolgast
				<i>Art Unit</i>	1624
				<i>Examiner Name</i>	Brenda Libby Coleman
Sheet	5	of	5	<i>Attorney Docket Number</i>	10426.0064-00000

NONPATENT LITERATURE DOCUMENTS

NONPATENT LITERATURE DOCUMENTS		
C89	Schaffner et al., "Preventing Severe Mental Illnesses - New Prospects and Ethical Challenges," <i>Schizophrenia Research</i> 51:3-15 (2001)	
C91	Smith et al., "Discovery and SAR of New Benzazepines as Potent and Selective 5-HT _{2c} Receptor Agonists for the Treatment of Obesity," <i>Bioorganic & Medicinal Chemistry Letters</i> 15(5):1467-1470 (2005)	
C94	Tsuang et al., "Towards the Prevention of Schizophrenia," <i>B245 Biol. Psychiatry</i> 48:349-356 (2000)	
C95	U.J. Griesser, "Polymorphism in the Pharmaceutical Industry," ed. Rolf Hilfiker, Wiley-VCH Verlag GmbH & Co.: pages 211-233 (2006)	
C99	Wise, "Addiction Becomes a Brain Disease," <i>Neuron</i> , 26: 27-33 (2000)	
C100	Wisner et al., "Postpartum Depression," <i>N. Engl. J. Med.</i> , 347(3):194-199 (2002)	
C101	Orito et al., "ALKYLATION OF 1,2,4,5-TERAHYDRO-3-METHYL-3H-3-BENZAZEPIN-2-ONE WITH SODIUM HYDRIDE AND ALKYL HALIDE," <i>Tetrahedron</i> 36:1017-1021 (1980) Pergamon Press Ltd.	
C108	Yoshinaga et al., "Prevention of Mildly Overweight Children from Development of More Overweight Condition," <i>Prevention Medicine</i> 38:172-174 (2004)	

Examiner Signature		Date Considered
--------------------	--	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.